{"result": {"id": "chatcmpl-368", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "**Brolusicumab**, also known as **Brolucizumab**, is a medication used to treat various eye conditions, particularly wet age-related macular degeneration (AMD). It works by reducing the number of injections needed for treatment and is effective in managing neovascular AMD.  Brolusicumab is an anti-VEGF antibody that helps manage abnormal blood vessel growth in the retina, commonly associated with AMD. It can also be used to treat other conditions like wet AMD and retinal diseases.  It's currently under study for various eye conditions, including central serous retinopathy (CSR) secondary to autoimmune diseases such as uveitis or ankylosing spondylitis. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743288480, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 138, "prompt_tokens": 367, "total_tokens": 505, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"BROLUCIZUMAB\"\nDescription List: [\"**Brolusicumab** is a medication used to treat **wet age-related macular degeneration (AMD)**. It reduces the number of injections needed for treatment and is also used for treating **MNV**, specifically type 1 and type 2 MNV.  It's a new anti-VEGF drug that has been studied in clinical trials for the treatment of **neovascular age-related macular degeneration (nAMD) and intermediate posterior ciliary vein (IPC)**.  Brolusicumab is also being used in research studies. \\n\", \"Brolucizumab is a medication currently under study for treating various eye conditions, including certain forms of age-related macular degeneration (AMD). It is an anti-VEGF antibody that helps manage neovascular AMD, a condition where abnormal blood vessels grow in the retina. Brolucizumab can also be used to treat wet AMD and retinal diseases.  It is often referred to as IB and has been used to treat central serous retinopathy (CSR) secondary to autoimmune diseases such as uveitis or ankylosing spondylitis. \\n\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_86002888f25476bb3dfb925a52ac81e18e7641960a20b7f2fea545cec4de1e57_v2"}